IQVIA Partners with AWS to Launch Agentic AI Platform for Clinical Trial Automation
核心洞察
IQVIA announced a strategic collaboration with Amazon Web Services (搜索), naming AWS (搜索) as its Preferred Agentic Cloud Provider to power next-generation AI platform capabilities.
The partnership aims to revolutionize clinical trial automation, medical affairs and analytics through an innovative agentic AI platform deployed on AWS (搜索) infrastructure.
With 90% of the world's largest pharmaceutical companies relying on both IQVIA and AWS (搜索), the collaboration seeks to democratize AI for life sciences and accelerate drug innovation.
IQVIA, a leading global provider of clinical research services, announced a strategic collaboration with Amazon Web Services (搜索) (AWS (搜索)) at AWS re:Invent, naming AWS as IQVIA's Preferred Agentic Cloud Provider. The partnership represents a major step in the digital transformation of healthcare and life sciences, aiming to revolutionize clinical trial automation, medical affairs and analytics through an innovative agentic AI platform.
Strategic Platform Deployment
Under the agreement, IQVIA will deploy its AI platform on AWS (搜索) to enhance scalable, secure and intelligent automation across clinical trial execution, medical affairs and healthcare analytics. The collaboration is specifically designed to improve clinical trial automation and accelerate trial processes, while IQVIA and AWS explore new opportunities in life science analytics to drive the next generation of data-driven insights and solutions.
The partnership leverages the fact that 90% of the world's largest pharmaceutical companies rely on both IQVIA and AWS (搜索) to power their digital transformation and analytics initiatives. This existing relationship positions the collaboration to democratize AI for life sciences, accelerate drug innovation and enable the faster delivery of life-saving treatments to patients around the globe.
Industry Leadership Perspectives
"We are excited to move forward with AWS (搜索) as IQVIA's Preferred Agentic Cloud Provider. Our AI platform aims to empower life sciences organizations to innovate faster and deliver treatments to patients more efficiently," said Lucas Glass, SVP, Architecture and Standards at IQVIA. "With agentic AI, we will unlock new possibilities for our clients and the industry at large."
Allyson Fryhoff, Director of Global Healthcare and Life Sciences at Amazon Web Services (搜索), emphasized the collaborative potential: "We are thrilled to support IQVIA's Agentic AI platform with the full breadth of AWS (搜索)'s cloud capabilities. Together, we aim to help the life sciences industry leverage the power of AI to support ongoing innovation in healthcare and achieve outcomes once thought impossible."
Technological Infrastructure
IQVIA's portfolio of solutions are powered by IQVIA Connected Intelligence to deliver actionable insights and services built on high-quality health data, Healthcare-grade AI, advanced analytics, the latest technologies and extensive domain expertise. The company is committed to using AI responsibly, with AI-powered capabilities built on best-in-class approaches to privacy, regulatory compliance and patient safety.
AWS (搜索) brings comprehensive cloud infrastructure to the partnership, offering more than 240 fully featured services for compute, storage, databases, networking, analytics, machine learning and artificial intelligence from 120 Availability Zones within 38 geographic regions. Since 2006, AWS has been the world's most comprehensive and broadly adopted cloud platform.
Global Impact and Scale
With approximately 91,000 employees in over 100 countries, IQVIA includes experts in healthcare, life sciences, data science, technology and operational excellence. The company is dedicated to accelerating the development and commercialization of innovative medical treatments to help improve patient outcomes and population health worldwide.
This strategic collaboration showcases a new era of agentic AI in life sciences, where intelligent cloud-powered solutions help drive greater efficiency, accelerate innovation and improve patient outcomes. The partnership positions both companies to support the life sciences industry's ongoing digital transformation and innovation in healthcare delivery.